Measuring and Optimizing Quality of Life in Metastatic RCC
As treatment options for metastatic renal cell carcinoma (RCC) have increased in number,…
Browsing Tag
RCC
Impact of TKI Combinations in Front-Line Treatment of RCC
Updated results presented at the American Society of Clinical Oncology (ASCO) annual meeting…
Long-Term Data in Frontline RCC Raise More Questions Than Answers
At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported…
What Does the Evidence Say About Immunotherapy Rechallenge in RCC?
Treatment of metastatic renal cell carcinoma (RCC) continues to rapidly evolve, with various…
No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCC
CHICAGO -- Adding atezolizumab (Tecentriq) to cabozantinib (Cabometyx) for patients with metastatic renal cell…
Post-Immunotherapy Combo Promising in Advanced RCC
Combination treatment with a hypoxia-inducible factor (HIF) 2α inhibitor and tyrosine kinase…
ICI/TKI Combo Maintains Survival Benefit in Advanced RCC
SAN FRANCISCO -- First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful…
Immune Stimulator May Enhance Targeted Therapy’s Activity in Metastatic RCC
AUSTIN, Texas -- A dendritic-cell immune primer failed to meet survival endpoints in a randomized trial of high-risk…
Clinical Challenges: First-Line Options for Metastatic RCC
Fifteen years ago, the average patient who walked into an oncology clinic with metastatic renal…
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA®…
BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer…